NCT04927793

Absorption, Metabolism, and Excretion (AME) Study of [14C]EDP-938 in Healthy Male Subjects

A Phase I, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]EDP-938 Following a Single Oral Dose in Healthy Male Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 8 (actual)
• Sponsor: Enanta Pharmaceuticals, Inc · Industry
• Sex: Male
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

A Phase 1, Open-label Study of the absorption, metabolism, and excretion of a single oral dose of \[14C\]EDP-938 in healthy male subjects.

Conditions

• Respiratory Syncytial Virus (RSV)

Interventions

Type	Name	Description
DRUG	EDP-938	\[14C\]EDP-938

Timeline

• Start date: 2021-05-28
• Primary completion: 2021-07-04
• Completion: 2021-07-04
• First posted: 2021-06-16
• Last updated: 2022-03-23

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study